Drug intelligence / Profile preview

SHR-1210 + BP102

Development stage: Unknown
Lead developer: Jiangsu HengRui Medicine Co., Ltd.
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

SHR-1210 + BP102 is a combination of two monoclonal antibodies. SHR-1210, also known as Camrelizumab, is a humanized monoclonal antibody targeting Programmed death 1 (PD-1), functioning as an immune checkpoint inhibitor to enhance anti-tumor immune responses. BP102 is a humanized recombinant monoclonal IgG1 antibody, although its specific target is not stated in the available data. This drug combination has been investigated for metastatic colorectal cancer in clinical trials, generally administered intravenously, and aims to improve objective response rate and progression-free survival in cancer patients[4][5].

Brand names: Camrelizumab (for SHR-1210)
Other names: Camrelizumab + BP102

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on SHR-1210 + BP102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SHR-1210 + BP102.